Selank Peptide Mitigates Large Intestine Damage from Chronic Stress in Rats
Background
Chronic psychological stress can profoundly impact the gastrointestinal system, often leading to conditions characterized by atrophy, inflammatory reactions, and dysregulation of immune cells like mast cells in the colon. This physiological response is frequently mediated by elevated stress hormones such as corticosterone. This study aimed to investigate whether the anxiolytic peptide Selank could protect the large intestine from the detrimental morphological changes induced by chronic restraint stress.
Results
Rats subjected to chronic restraint stress exhibited significant pathological changes in the colon, including clear signs of atrophy, a pronounced inflammatory reaction, and alterations in the number and functional activity of mast cells, all correlated with elevated corticosterone levels. Selank administration demonstrated a dose-dependent protective effect against these stress-induced manifestations. > Selank treatment significantly reduced elevated corticosterone levels and markedly attenuated the pathomorphological damage in the large intestine, leading to a substantial improvement in tissue integrity compared to untreated stressed controls. The peptide facilitated an accelerated adaptation to stress, with the 750 μg/kg dose showing the most pronounced beneficial impact on colonic morphology and inflammation.
Why It Matters
This research highlights Selank's potential as a therapeutic agent for mitigating stress-induced gastrointestinal pathology. By reducing systemic stress markers like corticosterone and directly improving colonic morphology, Selank offers a dual benefit for managing the complex interplay between psychological stress and physical health. These findings suggest Selank could be a promising candidate for future clinical development in treating stress-related digestive disorders, such as irritable bowel syndrome or inflammatory bowel disease. Further research, including detailed mechanistic studies and potentially human clinical trials, is warranted to fully explore its therapeutic utility.